CLDX Q4 2018 Earnings — Celldex Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CLDXCelldex Therapeutics, Inc.

$2B

Q4 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M-49.0% YoY

Gross Profit

-$8M-478.6% margin

Operating Income

-$12M-687.2% margin

Net Income

-$9M-533.0% margin

EPS (Diluted)

$-0.81

QoQ Revenue Growth

+87.5%

Cash Flow

Operating Cash Flow

-$15M

Free Cash Flow

-$16M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$156M

Total Liabilities

$32M

Stockholders' Equity

$124M

Cash & Equivalents

$24M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$3M	-49.0%
Gross Profit	-$8M	-$20M	+57.8%
Operating Income	-$12M	-$26M	+52.5%
Net Income	-$9M	-$4M	-144.8%